I ACUITY- studiets arm A blev UFH eller enoxaparin administreret i henhold til relevante retningslinier for AKS- patienter med UA og NSTEMI.
10 In Arm A of the ACUITY trial, UFH or enoxaparin was administered in accordance with the relevant guidelines for the management of ACS in patients with UA and NSTEMI.